地特胰岛素联合门冬胰岛素治疗妊娠合并糖尿病患者的安全性及有效性研究
发布时间：2019-07-02 10:56
【摘要】：目的分析对比地特胰岛素联合门冬胰岛素与精蛋白生物合成人胰岛素联合门冬胰岛素治疗妊娠合并糖尿病患者的安全性、有效性及分娩结局。方法选取2013年1月至2014年12月接受孕期检查并分娩的需用基础-餐前胰岛素治疗的妊娠合并糖尿病患者110例,其中,孕前糖尿病合并妊娠(PGDM)50例,GDM 60例,按1:1比例随机分为地特胰岛素组(Det,n=55)及精蛋白生物合成人胰岛素组(NPH,n=55)。Det组予地特胰岛素联合门冬胰岛素治疗;NPH组予精蛋白生物合成人胰岛素联合门冬胰岛素治疗。对比两组胰岛素治疗前后血糖变化、血糖达标时间、治疗期间低血糖发生率及分娩结局。结果治疗1周后,与NPH组比较,Det组平均2 hPG[(7.6±1.1)vs(6.9±0.9)mmol/L]降低(P=0.001);Det组血糖达标时间[FPG(7.1±3.2)vs(4.8±2.9)d;2 hPG(8.7±3.0)vs(5.7±3.6)d;FPG及2 hPG均达标(10.9±2.8)vs(6.8±4.1)d]均缩短(P=0.000)。Det组及NPH组治疗期间低血糖发生率分别为10.9%、25.5%,差异有统计学意义(P0.05)。两组分娩孕周、剖宫产率、妊娠期高血压、巨大儿,新生儿低血糖、新生儿高胆红素血症、新生儿体重及转NICU比较,差异均无统计学意义(P0.05)。结论对于妊娠合并糖尿病者,地特胰岛素联合门冬胰岛素能更快、更有效地控制血糖,明显减少注射次数和低血糖发生率,未增加不良分娩结局。
[Abstract]:Objective to analyze and compare the safety, efficacy and delivery outcome of Diet insulin combined with protophthora insulin and protamine biological synthetic human insulin combined with portal insulin in the treatment of gestational diabetes mellitus (GDM). Methods from January 2013 to December 2014, 110 pregnant patients with diabetes mellitus were selected, including 50 cases of pre-pregnancy diabetes mellitus complicated with gestational (PGDM) and 60 cases of GDM. According to the proportion of 1:1, they were randomly divided into two groups: Diet insulin group (Det,n=55) and protamine biosynchronous human insulin group (NPH,n=55). Det group treated with Diet insulin combined with insulin in winter), among them, 50 cases of prepregnancy diabetes complicated with diabetes mellitus and 60 cases of GDM were randomly divided into two groups according to the proportion of 1:1. NPH group was treated with protamine biosynthesized human insulin combined with asparagus insulin. The changes of blood glucose, the time of blood glucose reaching the standard, the incidence of hypoglycemia during treatment and the outcome of delivery were compared between the two groups before and after insulin treatment. Results one week after treatment, the mean 2 hPG [(7.6 卤1.1) vs (6.9) mmol/L] in Det group was lower than that in NPH group [(7.1 卤3.2) vs (4.8 卤2.9) d vs 2 hPG (8.7 卤3.0) vs (5.7 卤3.6) d] in P 鈮，
本文编号：2508878
[Abstract]:Objective to analyze and compare the safety, efficacy and delivery outcome of Diet insulin combined with protophthora insulin and protamine biological synthetic human insulin combined with portal insulin in the treatment of gestational diabetes mellitus (GDM). Methods from January 2013 to December 2014, 110 pregnant patients with diabetes mellitus were selected, including 50 cases of pre-pregnancy diabetes mellitus complicated with gestational (PGDM) and 60 cases of GDM. According to the proportion of 1:1, they were randomly divided into two groups: Diet insulin group (Det,n=55) and protamine biosynchronous human insulin group (NPH,n=55). Det group treated with Diet insulin combined with insulin in winter), among them, 50 cases of prepregnancy diabetes complicated with diabetes mellitus and 60 cases of GDM were randomly divided into two groups according to the proportion of 1:1. NPH group was treated with protamine biosynthesized human insulin combined with asparagus insulin. The changes of blood glucose, the time of blood glucose reaching the standard, the incidence of hypoglycemia during treatment and the outcome of delivery were compared between the two groups before and after insulin treatment. Results one week after treatment, the mean 2 hPG [(7.6 卤1.1) vs (6.9) mmol/L] in Det group was lower than that in NPH group [(7.1 卤3.2) vs (4.8 卤2.9) d vs 2 hPG (8.7 卤3.0) vs (5.7 卤3.6) d] in P 鈮，
本文编号：2508878
本文链接：https://www.wllwen.com/yixuelunwen/fuchankeerkelunwen/2508878.html
最近更新
教材专著
